<DOC>
	<DOCNO>NCT00198380</DOCNO>
	<brief_summary>Pneumonic adenocarcinoma ( P-ADC ) define primary lung ADC radiological pneumonic presentation , usually refer histologically ADC mixed-invasive BAC predominant subtype 2004 WHO classification . Surgery best therapy resectable tumor since effectiveness chemotherapy disappointing . In advanced P-ADC diffuse/multifocal type BAC , epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor ( TKIs ) ( gefitinib erlotinib ) show promise , rapid , dramatic response , possibly reflect specific molecular difference non-small cell lung carcinoma .</brief_summary>
	<brief_title>Treatment Lung Adenocarcinoma With Bronchioloalveolar Feature</brief_title>
	<detailed_description>We therefore conduct French multicentric phase II trial ( IFCT 0401 ) evaluate activity tolerance gefitinib ( 250 mg/day ) administer first line treatment patient non-resectable P-ADC .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Pathologically / cytologically proven ADCP Nonresectable disease 3month expect survival No prior radiotherapy chemotherapy Age &gt; = 18 year old Performance status &lt; 4 ( WHO ) Adequate blood biological parameter Abnormal initial fibroscopy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Adenocarcinoma , Bronchiolo-Alveolar</keyword>
</DOC>